Publications and communications of SERVAIS, Sophie

SERVAIS, S., BEGUIN, Y., & BARON, F. (2022). Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia. Stem Cells Translational Medicine. doi:10.1093/stcltm/szac015

GREGOIRE, C., SERVAIS, S., WILLEMS, E., BAUDOUX, E., LECHANTEUR, C., BRIQUET, A., Bettonville, V., DETRY, O., ERPICUM, P., JOURET, F., LOUIS, E., BARON, F., & BEGUIN, Y. (April 2022). Immunothérapie cellulaire au CHU de Liège : avancées, défis et perspectives. Revue Médicale de Liège, 77 (4), 206-211.

Canti, L., Ariën, K. K., Desombere, I., Humblet-Baron, S., Pannus, P., Heyndrickx, L., HENRY, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., SEIDEL, L., Michiels, J., Willems, B., Goossens, M. E., Beguin, Y., Marchant, A., & Baron, F. (2022). Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients. Cancer Cell. doi:10.1016/j.ccell.2022.02.005

Canti, L.* , Humblet-Baron, S.* , Desombere, I., Neumann, J., Pannus, P., Heyndrickx, L., Henry, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., Seidel, L., Michiels, J., Willems, B., Liston, A., Ariën, K. K., Beguin, Y., Goossens, M. E., Marchant, A., & Baron, F. (2021). Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. Journal of hematology & oncology, 14 (1), 174. doi:10.1186/s13045-021-01190-3

Catalano, C., SERVAIS, S., BONVOISIN, C., Couturier, B., Hildebrand, M., Etienne, I., MEURIS, C., Goffard, J.-C., Wissing, M., Goldman, M., & Le Moine, A. (2021). Preemptive Antibody Therapy for Vaccine Breakthrough SARS-CoV-2 Infection in Immunocompromised Patients. Transplantation, 105, 282. doi:10.1097/TP.0000000000003942

Courtois, J., Ritacco, C., DUBOIS, S., Canti, L., Vandenhove, B., SEIDEL, L., Daulne, C., CAERS, J., SERVAIS, S., Beguin, Y., Ehx, G., & BARON, F. (2021). Itacitinib prevents xenogeneic GVHD in humanized mice. Bone Marrow Transplantation, 56, 2672-2681. doi:10.1038/s41409-021-01363-1

Ehx, G., Ritacco, C., HANNON, M., DUBOIS, S., Delens, L., WILLEMS, E., SERVAIS, S., Drion, P., BEGUIN, Y., & Baron, F. (2021). Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis. American Journal of Transplantation, 21, 2662-2674. doi:10.1111/ajt.16505

MAQUET, C., BEGUIN, Y., DE PRIJCK, B., WILLEMS, E., SERVAIS, S., & BONNET, C. (2021). Le lymphome diffus à grandes cellules B : nouveau traitement révolutionnaire par des cellules immunitaires génétiquement modifiées appelées «CAR T cells». Revue Médicale de Liège, 76, 476-481.

Narinx, J., SERVAIS, S., BARON, F., BEGUIN, Y., & WILLEMS, E. (2021). Allogreffes de cellules souches hématopoïétiques : principes généraux et progrès récents. Revue Médicale de Liège, 76, 464-469.

Ritacco, C., Ehx, G., GREGOIRE, C., Daulne, C., WILLEMS, E., SERVAIS, S., BEGUIN, Y., & Baron, F. (2021). High proportion of terminally-differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 56, 1828-1841. doi:10.1038/s41409-021-01221-0

Rubio, M., Varlet, P., Allain, V., Ballot, C., Cuffel, A., Deschamps, M., Ferrand, C., FOGUENNE, J., Forcade, E., Huynh, A., Guihot, A., Latouche, J.-B., Lemarie, C., Martinroche, G., Morin, F., Nguyen, S., SCHMIT, K., SERVAIS, S., Simonetta, F., & Zucman, S. (2021). Suivi immunologique des patients traités par cellules CAR-T pour hémopathie maligne: recommandations du groupe CARTi et de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Bulletin du Cancer, 108, 53-S64. doi:10.1016/j.bulcan.2021.04.008

Vandenhove, B., Canti, L., Schoemans, H., Beguin, Y., Baron, F., Graux, C., Kerre, T., & SERVAIS, S. (21 October 2020). How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation. Frontiers in Immunology, 11, 583564. doi:10.3389/fimmu.2020.583564

Ritacco, C., Ehx, G., Canti, L., DUBOIS, S., Vandenhove, B., SERVAIS, S., Beguin, Y., & Baron, F. (01 March 2020). Ptcy Prevents Xenogeneic Gvhd without Abrogating Gvl Effects. Biology of Blood and Marrow Transplantation, 26 (3), 168. doi:10.1016/j.bbmt.2019.12.028

Vandenhove, B.* , Canti, L.* , Schoemans, H., BEGUIN, Y., BARON, F., WILLEMS, E., Graux, C., Kerre, T.* , & SERVAIS, S.*. (2020). Acute graft-versus-host disease: diagnosis, pathophysiology and prevention. Belgian Journal of Hematology, 11 (4), 159-173.

Mina, M., Horrion Jil, SERVAIS, S., BEGUIN, Y., DRESSE, M.-F., MALAISE, M., & MALAISE, O. (September 2019). Multiple vertebral fractures after bone marrow transplantation in a young patient with sickle cell disease? Paper presented at Belgian Congress of Rheumatology.

Mina, M., Horrion, J., SERVAIS, S., BEGUIN, Y., DRESSE, M.-F., Malaise, M., & MALAISE, O. (March 2019). Multiple vertebral fractures after bone marrow transplantation in a young patient with sickle cell disease? Paper presented at Bone Curriculum Symposium 2019.

Delens, L., Ehx, G., SOMJA, J., Vrancken, L., Belle, L., SEIDEL, L., Grégoire, C., Fransolet, G., Ritacco, C., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & Servais, S. (2019). In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 204-215. doi:10.1016/j.bbmt.2018.10.007

Dendoncker, C., Brouillat, C., Daufrene, L., Deledicque, V., Cheikh, J. E., Gibault-Joffe, C., Guilbert, Y., Guidi, V., Hadrot, L., Haran, I., Kermeur, G., Kernoa, K., L'Hostette, A., Mercier, L., Mouneydier, K., SERVAIS, S., WITHOFS, S., Yakoub-Agha, I., & Farrugia, C. (2019). Oral feeding of patient hospitalized for allogeneic stem cells transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) [Alimentation orale du patient hospitalisé pour une allogreffe de cellules souches hématopoïétiques : recommandations de la Société Francophone de Greffe de Mœlle et de Thérapie Cellulaire (SFGM-TC)]. Bulletin du Cancer. doi:10.1016/j.bulcan.2019.07.010

Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619

Pirotte, M., Forte, F., Lutteri, L., WILLEMS, E., DURAN, U., Belle, L., Baron, F., BEGUIN, Y., Maquet, P., BODART, O., & Servais, S. (2018). Neuronal surface antibody-mediated encephalopathy as manifestation of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Journal of Neuroimmunology, 323, 115-118. doi:10.1016/j.jneuroim.2018.08.003

Servais, S., Baron, F., LECHANTEUR, C., SEIDEL, L., Selleslag, D., Maertens, J., BAUDOUX, E., Zachee, P., Van Gelder, M., Noens, L., Kerre, T., Lewalle, P., Schroyens, W., ORY, A., & Beguin, Y. (2018). Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graftversus- host disease: A multicenter prospective study. Oncotarget, 9 (29), 20590-20604. doi:10.18632/oncotarget.25020

Vrancken, L., Muller, J., Lejeune, M., Grégoire, C., Delens, L., Jaspers, A., Servais, S., DE PRIJCK, B., Baron, F., Caers, J., & Beguin, Y. (2018). Nouveautes dans la prise en charge du myelome. Revue Médicale Suisse, 14 (615), 1438-1442.

Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, F., & BARON, F. (24 May 2017). Th17 cells impact on xenogeneic graft-versus-host disease. Poster session presented at 2017 Immunology day FNRS-Immunology Doctoral School, Gosselies, Belgium.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., Beguin, Y., & Baron, F. (27 March 2017). Xenogeneic graft-versus-host disease : Impact of Th17 cells. Poster session presented at 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, Marseille, France.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & BARON, F. (February 2017). Impact of Th17 population on xenogeneic graft-versus-host disease. Poster session presented at 32nd General Annual Meeting of the Belgian Hematology Society, La Hulpe, Belgium.

SERVAIS, S., Hannon, M., Peffault de Latour, R., Socie, G., & BEGUIN, Y. (2017). Reconstitution of adaptive immunity after umbilical cord blood transplantation and clinical implication regarding risk of infections. Stem Cell Investigation, 4, 40.

Vrancken, L., Delens, L., BEGUIN, Y., BARON, F., & SERVAIS, S. (2017). Focus sur les lymphocytes T dans la maladie du greffon contre l'hôte après allogreffe de cellules soucges hématopoïétiques: implications pour de nouvelles stratégies de prévention. Onco: Revue Multidisciplinaire d'Oncologie, 11, 23-31.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & Baron, F. (08 December 2016). Xenogeneic graft-versus-host disease: Impact of Th17 cells. Poster session presented at Journée des chercheurs Télévie 2017, Bruxelles, Belgium.

Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & BARON, F. (18 November 2016). Impact des cellules Th17 sur la GVH xénogénique. Paper presented at 16ème édition du congrès de la SFGM-TC, Société Francophone de Greffe de Moelle et de Thérapie Cellulaire, Liège, Belgium.

Bay, Dendoncker, C., Angeli, M., BIOT, T., Chikhi, M., Combal, C., Jouannic, L., Kermeur, G., Lopvet, L., Marchand, T., Schmitt, S., SERVAIS, S., Yakoub-Agha, I., & Seguy, D. (November 2016). Nutritional management for patients hospitalized during allogeneic stem cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Bulletin du Cancer, 103 (11S), 201-S206. doi:10.1016/j.bulcan.2016.09.014

SID, S., Baron, F., WILLEMS, E., Caers, J., Bonnet, C., DE PRIJCK, B., LEJEUNE, M., HAFRAOUI, K., Servais, S., JASPERS, A., & Beguin, Y. (November 2016). Hematologic recovery after autologus stem cell transplantation in multiple myeloma: a single center experience of 225 patients. Paper presented at 16ème Congrès commun de la SFGM-TC & 8ème de la SFBCT, Liège, Belgium.

Glauzy, S., Peffault de Latour, R., André-Schmutz, I., Lachuer, J., SERVAIS, S., SOCIE, G., CLAVE, E., & TOUBERT, A. (September 2016). Alterations of circulating lymphoid committed progenitor cellular metabolism after allogeneic stem cell transplantation in humans. Experimental Hematology, 44 (9), 811-816. doi:10.1016/j.exphem.2016.05.008

Delens, L., BEGUIN, Y., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., SERVAIS, S., & BARON, F. (27 May 2016). Th17 cell population seems to aggravate xenogeneic graft-versus-host disease. Poster session presented at 2016 Immunology day FNRS-Immunology Doctoral School, Gosselies, Belgium.

SERVAIS, S., BEGUIN, Y., Delens, L., Ehx, G., Fransolet, G., Hannon, M., WILLEMS, E., Humblet-Baron, S., Belle, L., & Baron, F. (11 May 2016). Novel approaches for preventing acute graftversus- host disease after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Investigational Drugs, 9, 957-972. doi:10.1080/13543784.2016.1182498

SERVAIS, S., DUMONTIER, N., BIARD, L., SCHNEPF, N., RESCHE-RIGON, M., PEFFAULT DE LATOUR, R., SCIEUX, C., ROBIN, M., MEUNIER, M., XHAARD, A., SICRE DE FONTBRUNE, F., LE GOFF, J., SOCIE, G., SIMON, F., & MAZERON, M.-C. (March 2016). Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status. Clinical Microbiology and Infection, 22 (3), 289e1-7. doi:10.1016/j.cmi.2015.11.006

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & Baron, F. (29 January 2016). Salt but not glucocorticoïds enhances Th17 differentiation from naïve T cells in vitro. Poster session presented at 31st General Annual Meeting of the Belgian Hematological Society, La Hulpe, Belgium.

SERVAIS, S., GREGOIRE, C., BARON, F., WILLEMS, E., BRIQUET, A., BAUDOUX, E., DELLOYE, O., GIET, O., LECHANTEUR, C., & BEGUIN, Y. (2016). Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Belgian Journal of Hematology, 7, 229-235.

Delens, L., Servais, S., Hannon, M., Ehx, G., Fransolet, G., DUBOIS, S., Daulne, C., Vrancken, L., Beguin, Y., & Baron, F. (03 December 2015). Revisiting Th17 cell subsets in the setting of allogeneic stem cell transplantation and (cortico-refractory) graft-versus-host disease. Poster session presented at Journée Télévie 2016, Gembloux, Belgium.

JASPERS, A., Baron, F., SERVAIS, S., LEJEUNE, M., WILLEMS, E., SEIDEL, L., HAFRAOUI, K., Bonnet, C., & Beguin, Y. (September 2015). Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival. American Journal of Hematology, 90 (9), 197-199. doi:10.1002/ajh.24100

HANNON, M., BEGUIN, Y., Ehx, G., SERVAIS, S., SEIDEL, L., Graux, C., Maertens, J., Kerre, T., Daulne, C., de Bock, M., Fillet, M., ORY, A., WILLEMS, E., GOTHOT, A., Humblet-Baron, S., & BARON, F. (15 July 2015). Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation following Flu-TBI versus TLI-ATG Conditioning. Clinical Cancer Research, 21 (14), 3131-9. doi:10.1158/1078-0432.CCR-14-3374

JASPERS, A., Baron, F., Maertens, J., DE PRIJCK, B., Schots, R., Bonnet, C., HAFRAOUI, K., WILLEMS, E., SERVAIS, S., FILLET, G., & Beguin, Y. (July 2015). Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation [letter to the editor]. American Journal of Hematology, 90 (7), 133-4. doi:10.1002/ajh.24013

Delens, L., SERVAIS, S., Hannon, M., Ehx, G., Fransolet, G., DUBOIS, S., Beguin, Y., & Baron, F. (30 January 2015). Effects of Tocilizumab on Th17 cell differentiation in a humanized mouse model of xenogeneic graft-versus-host disease. Poster session presented at 30st General Annual Meeting of the Belgian Hematological Society, La Hulpe, Belgium.

SERVAIS, S., Baron, F., & BEGUIN, Y. (2015). Impact of graft source and composition on outcomes after allogeneic stem cell transplantation. Belgian Journal of Hematology, 6 (4), 162-168.

Servais, S., BAUDOUX, E., Brichard, B., Bron, D., Debruyn, C., De Bruyère, M., De Hemptinne, D., Deneys, V., Paulus, J.-M., Raymakers, N., Schaaps, J.-P., Van Cauwenberge, J., Cornu, G., Delforge, A., & Beguin, Y. (January 2015). Circadian and circannual variations in cord blood hematopoietic cell composition. Haematologica, 100 (1), 32-34. doi:10.3324/haematol.2014.115394

SERVAIS, S., Menten-Dedoyart, C., Beguin, Y., SEIDEL, L., Gothot, A., Daulne, C., WILLEMS, E., Delens, L., Humblet-Baron, S., Hannon, M., & Baron, F. (2015). Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation. PLoS ONE, 10 (6), 0130026. doi:10.1371/journal.pone.0130026

JASPERS, A., BARON, F., MAERTENS, J., DE PRIJCK, B., SCHOTS, H., BONNET, C., HAFRAOUI, K., WILLEMS, E., SERVAIS, S., FILLET, G., & BEGUIN, Y. (December 2014). Long-term safety follow-up of a rendomized trial of Darbepoetin Alpha and intravenous iron following autologous hematopoietic cell transplantation. Blood, 124 (21), 3948.

SERVAIS, S., Lengline, E., Porcher, R., Carmagnat, M., Peffault de Latour, R., Robin, M., Sicre de Fontebrune, F., Clave, E., Maki, G., Granier, C., Xhaard, A., Dhedin, N., Molina, J.-M., Toubert, A., Moins-Teisserenc, H., & Socie, G. (April 2014). Long term Immune Reconstitution and infection burden after Mismatched Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 20 (4), 507-517. doi:10.1016/j.bbmt.2014.01.001

Glauzy, S., André-Schmutz, I., Larghero, J., Ezine, S., Peffault de Latour, R., Moins-Teisserenc, H., SERVAIS, S., Robin, M., Socie, G., Clave, E., & Toubert, A. (12 March 2014). CXCR4-related increase of circulating human lymphoid progenitors after allogeneic hematopoietic stem cell transplantation. PLoS ONE, 9 (3), 91492. doi:10.1371/journal.pone.0091492

de Masson, A., Beylot-Barry, M., Bouaziz, J.-D., Peffault de Latour, R., Aubin, F., Garciaz, S., d’Incan, M., Dereure, O., Dalle, S., Dompmartin, A., Suarez, F., Battistella, M., Vignon-Pennamen, M.-D., Rivet, J., Adamski, H., Brice, P., Sylvie, F., Lissandre, S., Turlure, P., & Bagot, M. (March 2014). Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica, 99 (3), 527-534. doi:10.3324/haematol.2013.098145

SERVAIS, S., Porcher, R., Xhaard, A., Robin, M., Masson, E., Larghero, J., Ribaud, P., Dhedin, N., Abbes, S., Sicre, F., Socie, G., & Peffault de Latour, R. (March 2014). Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related/unrelated donors. Haematologica, 99 (3), 519-526. doi:10.3324/haematol.2013.089979

Baron, F., Humblet-Baron, S., Ehx, G., SERVAIS, S., HANNON, M., Belle, L., LECHANTEUR, C., BRIQUET, A., GIET, O., BAUDOUX, E., WILLEMS, E., & Beguin, Y. (2014). Thinking out of the box - New approaches to controlling GVHD. Current Hematologic Malignancy Reports, 9, 73-84. doi:10.1007/s11899-013-0187-9

Servais, S., Lenglinne, E., Porcher, R., Carmagnat, M., Peffault de Latour, R., Maki, G., Clémence, G., Robin, M., Clave, E., Xhaard, A., Dhedin, N., Toubert, A., Moins-Teisserenc, H., & Socie, G. (08 April 2013). Immune Reconstitution After Alternative Hematopoietic Stem Cell Transplantation: Comparison of Unrelated Cord Blood and Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation. Bone Marrow Transplantation, 48 (S2), 132.

Servais, S., Porcher, R., Xhaard, A., Robin, M., Masson, E., Larghero, J., Ribaud, P., Dhedin, N., Abbes, S., Sicre, F., Socie, G., & Peffault de Latour, R. (25 January 2013). Donor Characteristics As Pretransplant Predictive Factors of Long-Term Outcomes After Allogeneic Peripheral Blood Stem Cell Transplantation From HLA-Matched Related and Unrelated Donors in Patients with Hematologic Malignancies. Paper presented at 28th General Meeting of the Belgian Hematological Society, Gand, Belgium.

BEGUIN, Y., Maertens, J., DE PRIJCK, B., Schots, R., Seidel, L., BONNET, C., HAFRAOUI, K., WILLEMS, E., Vanstraelen, G., SERVAIS, S., JASPERS, A., FILLET, G., & BARON, F. (2013). Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation : A prospective multicenter randomized trial. American Journal of Hematology, 88, 990-996. doi:10.1002/ajh.23552

SERVAIS, S., Beguin, Y., & Baron, F. (2013). Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Emerging Drugs, 18 (2), 173-192. doi:10.1517/14728214.2013.798642

SERVAIS, S., WILLEMS, E., Beguin, Y., & Baron, F. (2013). Allogreffe de cellules souches hématopoïétiques chez le patient âgé : jusqu'à quel âge ? Revue Médicale de Liège, 68 (1), 38-43.

Servais, S., Porcher, R., Robin, M., Xhaard, A., Masson, E., Larghero, J., Ribaud, P., Dhedin, N., Abbes, S., Socie, G., & Peffault de Latour, R. (November 2012). Donor Characteristics As Pretransplant Predictive Factors of Long-Term Outcomes After Allogeneic Peripheral Blood Stem Cell Transplantation From HLA-Matched Related and Unrelated Donors in Patients with Hematologic Malignancies. Blood, 120, 2000.

SERVAIS, S., Hannon, M., Daulne, C., Gothot, A., Beguin, Y., & Baron, F. (February 2012). Longitudinal Monitoring of Immune Reconstitution after Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): Impact of T-Cell Depletion of the Graft. Biology of Blood and Marrow Transplantation, 18 (2), 274-S275. doi:10.1016/j.bbmt.2011.12.193

Baron, F., & SERVAIS, S. (2012). Rituximab et maladie du greffon contre l'hôte chronique. Horizons Hemato, 2 (2), 78-81.

FRUSCH, N., SERVAIS, S., DE PRIJCK, B., Corhay, J.-L., Beguin, Y., Louis, R., & DUYSINX, B. (2012). Spontaneous pneumomediastinum caused by bleomycin-induced pneumonitis. Acta Clinica Belgica, 67-68. doi:10.2143/ACB.67.5.2062693

Malaise, O., FRUSCH, N., BECK, E., Servais, S., BETEA, D., CAERS, J., DE PRIJCK, B., & BEGUIN, Y. (2012). Panhypopituitarism and diabetus insipidus in a patient with primary central nervous system lymphoma. Leukemia and Lymphoma, 53 (12), 2515-16.

SERVAIS, S., & Baron, F. (2012). Allogreffe de cellules souches hématopoïétiques après conditionnements réduits ("minigreffes") comme traitement de certaines pathologies hématologiques malignes. Onco: Revue Multidisciplinaire d'Oncologie, 6, 6-12.

VERTENOEIL, G., SERVAIS, S., & Beguin, Y. (2012). Comment j'explore... une fièvre d'origine indéterminée chez le patient adulte ? Revue Médicale de Liège, 67 (7-8), 391-397.

Belle, L., Baron, F., Bruck, F., Hannon, M., Servais, S., Beguin, Y., & BRIQUET, A. (2011). Despite Inhibitory Effects on Normal Hematopoiesis in Vitro, Imatinib and Nilotinib do not Prevent Engraftment of Human CD34+ HSCs in immunodeficient NSG Mice. Poster session presented at 26th General Meeting of the Belgian Hematological Society.

Belle, L., Baron, F., Bruck, F., Hannon, M., SERVAIS, S., Beguin, Y., & BRIQUET, A. (2011). Despite inhibitory effects on normal hematopoiesis in vitro, Imatinib and Nilotinib do not prevent engraftment of human CD34+ HSCs in immunodeficient NSG mice. Belgian Journal of Hematology.

SERVAIS, S., Baron, F., & Beguin, Y. (2011). Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning. Transfusion and Apheresis Science, 44, 205-210. doi:10.1016/j.transci.2011.01.019

Servais, S., Beguin, Y., & Baron, F. (2011). Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation (HSCT). Belgian Journal of Hematology, 2, 3-9.

SERVAIS, S., Hannon, M., Daulne, C., Gothot, A., Beguin, Y., & Baron, F. (2011). Longitudinal Monitoring of Immune Reconstitution After Allogeneic Peripheral Blood Stem Cell Transplantation (HSCT): Impact of T Cell Depletion of the Graft. Belgian Journal of Hematology, Abstracts book (Supplement of 26th General Meeting of the Belgian Hematological Society), 31.

Servais, S., Caers, J., Warling, O., Frusch, N., Baron, F., De Prijck, B., & Beguin, Y. (2010). Enteroviral meningoencephalitis as complication of Rituximab therapy in a patient treated for diffuse large B-cell lymphoma. British Journal of Haematology, 150 (3), 379-381. doi:10.1111/j.1365-2141.2010.08202.x

Servais, S., Willems, E., Beguin, Y., & Baron, F. (2010). Maladie du greffon contre l'hôte chronique : une prise en charge multidisciplinaire. Revue Médicale de Liège, 65, 81-87.

Beguin, Y., Maertens, J., DE PRIJCK, B., Schots, R., Frère, P., Bonnet, C., HAFRAOUI, K., WILLEMS, E., Vanstraelen, G., LEJEUNE, M., SERVAIS, S., THeunissen, K., Fillet, G., & Baron, F. (2009). A prospective randomized multicenter trial of darbepoetin-alfa and I.V. iron administration after autologous hematopoietic stem cell transplantation. Poster session presented at 24th General Meeting of the Belgian Hematological Society, Oostende, Belgium.

Debabeche, C., Muselle, A., Servais, S., Farcy, L., Barbier, V., Laloyaux, C., Mikolajczak, G., & Desseilles, M. (2009). Trouble obsessionnel-compulsif (TOC). Revue Médicale Suisse, 5 (214), 1659-62.

Servais, S., Ansseau, M., Mikolajczak, G., & Desseilles, M. (2008). L'électroconvulsivothérapie en 2008. Revue Médicale de Liège, 63, 404-410.